Wall Street analyst estimates for Connect Biopharma Holdings Limited (CNTB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.27 | ||
| 2026-08-12 | $-0.27 | $-0.31 | +14.3% |
| 2026-05-12 | $-0.34 | $-0.29 | -17.2% |
| 2026-03-31 | $-0.27 | $-0.30 | +10.0% |
| 2025-11-12 | $-0.04 | $-0.03 | -29.7% |
| 2025-08-13 | $-0.03 | $-0.22 | +85.4% |
| 2025-05-15 | $-0.03 | $-0.26 | +89.9% |
| 2025-03-31 | $-0.06 | $-0.26 | +77.9% |
Valuation Ratios
| Price / Book | 2.31 |
| EV / EBITDA | -2.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $26.0M | $64000 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | $26.0M | $64000 |
| Research & Development | $15.4M | $23.1M | $80.5M | $96.6M | $53.0M | $29.3M | $37.8M |
| Selling, General & Admin | $1.4M | $7.3M | $19.0M | $20.8M | $16.1M | $19.2M | $20.3M |
| Operating Expenses | $16.4M | $29.4M | $98.1M | $119.3M | $69.1M | $48.5M | $58.1M |
| Operating Income | -$16.0M | -$30.3M | -$98.1M | -$119.3M | -$69.1M | -$22.5M | -$58.1M |
| EBITDA | -$24.8M | -$118.2M | -$201.4M | -$116.7M | -$61.3M | -$14.7M | -$54.6M |
| Interest Expense | $7689 | $6434 | $6909 | $21032 | 0 | 0 | 0 |
| Pre-tax Income | -$24.5M | -$119.4M | -$202.0M | -$117.8M | -$62.0M | -$15.4M | -$55.3M |
| Income Tax | 0 | 0 | $266000 | $298000 | $120000 | $223000 | $197000 |
| Net Income | -$24.5M | -$119.4M | -$202.3M | -$118.1M | -$62.1M | -$15.6M | -$55.5M |
| EPS | $-3.02 | $-14.45 | $-25.00 | $-14.50 | $-1.08 | $-0.28 | $-1.00 |
| EPS (Diluted) | $-3.02 | $-14.45 | $-25.00 | $-14.50 | $-1.08 | $-0.28 | $-1.00 |
| Shares Outstanding (Diluted) | $55.8M | $53.9M | $52.3M | $55.0M | $55.1M | $55.2M | $55.7M |
Price
| Price | $1.24 |
| Market Cap | $78M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARTV · CNTX · IFRX · IMA · KLRS · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of CNTB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks